2020
DOI: 10.2147/ccid.s292636
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…28 Topical PEA 0.3% formulations decreased VAS and verbal itching rating scale (VRS) scores, reduced transepidermal water loss, and improved sleep quality in patients with chronic pruritus. 29,30 A phase II RCT of an oral CB2 agonist (lenabasum 5 mg, 20 mg, 40 mg daily) safely improved skin burden, patient-reported function, and inflammation and fibrosis under skin histology with diffuse cutaneous systemic sclerosis. 31 Cases of individual patients with recalcitrant inflammatory skin disease or preference for "natural" treatments, resolving with topical medical cannabinoids, are increasingly reported, 4,6,32,33 emphasizing the need for further, well-designed clinical trials assessing safety and efficacy in larger samples.…”
Section: Applications In Dermatologymentioning
confidence: 99%
“…28 Topical PEA 0.3% formulations decreased VAS and verbal itching rating scale (VRS) scores, reduced transepidermal water loss, and improved sleep quality in patients with chronic pruritus. 29,30 A phase II RCT of an oral CB2 agonist (lenabasum 5 mg, 20 mg, 40 mg daily) safely improved skin burden, patient-reported function, and inflammation and fibrosis under skin histology with diffuse cutaneous systemic sclerosis. 31 Cases of individual patients with recalcitrant inflammatory skin disease or preference for "natural" treatments, resolving with topical medical cannabinoids, are increasingly reported, 4,6,32,33 emphasizing the need for further, well-designed clinical trials assessing safety and efficacy in larger samples.…”
Section: Applications In Dermatologymentioning
confidence: 99%